Background: Switching to the 2-drug regimen dolutegravir + rilpivirine demonstrated noninferiority vs continuing a 3-drug or 4-drug current antiretroviral regimen (CAR) at week 48 and maintained high levels of virologic suppression to week 148 in the SWORD studies. We report inflammation and atherogenesis biomarkers postswitch to dolutegravir + rilpivirine.
Setting: SWORD-1: 65 centers, 13 countries; SWORD-2: 60 centers, 11 countries.
Methods: Virologically suppressed adults were randomized to switch to dolutegravir + rilpivirine (early-switch group; n = 513) or continue CAR (n = 511). Participants continuing CAR switched to dolutegravir + rilpivirine at week 52 (late-switch group; n = 477). Biomarkers were evaluated from Baseline to week 48 for dolutegravir + rilpivirine and CAR and noncomparatively for dolutegravir + rilpivirine postswitch through 148 weeks (early-switch) and 96 weeks (late-switch).
Results: Through week 48, changes in biomarkers did not significantly differ between dolutegravir + rilpivirine and CAR groups, except for increases in soluble CD14 and decreases in fatty acid-binding protein-2, which favored dolutegravir + rilpivirine. For inflammation biomarkers through week 148, there was no marked change in C-reactive protein, inconsistent changes in soluble CD14 and interleukin-6, and increases in soluble CD163. For atherogenesis biomarkers through week 148, fatty acid-binding protein-2 and soluble vascular cell adhesion molecule-1 showed sustained reductions; D-dimer showed inconsistent increases between early-switch vs late-switch groups.
Conclusions: No consistent pattern of change in biomarkers postswitch to dolutegravir + rilpivirine was observed through weeks 48 and 148 in SWORD-1/SWORD-2, suggesting no association of increased inflammation or atherogenesis with the 2-drug regimen while maintaining virologic suppression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377491 | PMC |
| http://dx.doi.org/10.1097/QAI.0000000000003019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis.
Infect Chemother
September 2024
Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy.
Article Synopsis
- The meta-analysis aimed to compare the efficacy and safety of two-drug regimens versus triple-drug regimens in virosuppressed people living with HIV (PLWH) over a 96-week follow-up period.
- The review included six studies, assessing treatment failure, virological failure, adverse drug reactions, and mutations, with no significant differences found between the two treatment approaches.
- The findings support the use of two-drug regimens as a simpler and effective treatment option for improving clinical outcomes in virosuppressed PLWH.
Pre- and Post-Exposure Prophylaxis for HIV in Patients Taking Anti-Seizure Medications.
Epilepsy Curr
May 2024
Department of Neurology, University of Texas Southwestern, Dallas, TX, USA.
Article Synopsis
- Recent advancements in HIV prevention highlight the effectiveness of pre- and post-exposure prophylaxis (PrEP and PEP), particularly in the context of new anti-seizure medications (ASMs) that have emerged since 2012.
- The review discusses the potential drug interactions between PrEP/PEP and various ASMs, particularly focusing on enzyme-inducing ASMs that may lower the effectiveness of tenofovir-containing treatments, as well as the impact of ritonavir on lamotrigine levels.
- Clinicians are encouraged to be aware of these interactions and side effects, such as osteopenia and gastrointestinal issues, to provide better care for patients who might be at risk for both seizures and HIV infection.
Development and emerging trends of drug resistance mutations in HIV: a bibliometric analysis based on CiteSpace.
Front Microbiol
May 2024
School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: Antiretroviral therapy has led to AIDS being a chronic disease. Nevertheless, the presence of constantly emerging drug resistance mutations poses a challenge to clinical treatment. A systematic analysis to summarize the advancements and uncharted territory of drug resistance mutations is urgently needed and may provide new clues for solving this problem.
View Article and Find Full Text PDFPRESTIGIO RING "a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests".
New Microbiol
May 2024
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Management of virological failure in heavily treatment-experienced people with multidrug-resistant (MDR) HIV infection is a serious clinical challenge. New drugs with novel mechanisms of action have recently been approved, and their use has improved the outcome of subjects with limited treatment options (LTO). In this setting, the choice of antiretroviral therapy (ART) should be tailored based on the pattern of resistance, treatment history and patients' individual characteristics.
View Article and Find Full Text PDFReal World Data of Viral Suppression With Darunavir/Cobicistat and Dolutegravir/Rilpivirine Among Treatment-Experienced Patients Living With Multidrug-Resistant HIV.
J Pharm Pract
December 2024
Program for AIDS Treatment and Health (PATH) Center, The Brooklyn Hospital Center, Brooklyn, NY, USA.
Despite the effectiveness of the TRIO regimen in maintaining viral suppression, as seen in the ANRS 139 TRIO trial, one drawback is the high pill burden. However, with the development of newer antiretrovirals, this regimen can be simplified. The combination of both co-formulated darunavir/cobicistat and dolutegravir/rilpivirine keeps the integrity of the TRIO regimen while decreasing daily pill count from 12 to 2 tablets daily.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!